Gatifloxacin

Antibiotic; Inhibits bacterial DNA gyrase and topoisomerase IV
Gatifloxacin

Antibiotic; Inhibits bacterial DNA gyrase and topoisomerase IV

1 g
Catalog # 72752
768 USD

Overview

Gatifloxacin is a fluoroquinolone antibiotic which inhibits bacterial DNA gyrase (IC₅₀ = 0.109 µg/ml) and topoisomerase IV (IC₅₀ = 13.8 µg/ml; Takei et al.). It is much less effective against HeLa cell topoisomerase II (IC₅₀ = 265 µg/ml; Takei et al.).

MAINTENANCE AND SELF-RENEWAL
· Promotes self-renewal in cultured human and mouse embryonic stem cells (Desbordes et al.).
Alternative Names
AM 1155; BMS 206584-01; PD 135432
Cell Type
Pluripotent Stem Cells
Species
Human, Mouse, Rat, Non-Human Primate, Other
Application
Antibiotic, Expansion, Maintenance
Area of Interest
Stem Cell Biology
CAS Number
112811-59-3
Chemical Formula
C₁₉H₂₂FN₃O₄
Molecular Weight
375.4 g/mol
Purity
≥ 98%

Scientific Resources

Product Documentation

Document Type Product Name Catalog # Lot # Language
Document Type
Product Information Sheet
Product Name
Gatifloxacin
Catalog #
72752
Lot #
All
Language
English
Document Type
Safety Data Sheet
Product Name
Gatifloxacin
Catalog #
72752
Lot #
All
Language
English

Educational Materials (1)

Mini Review
Small Molecules

Product Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Data and Publications

Publications (2)

Cell stem cell 2008 JUN High-throughput screening assay for the identification of compounds regulating self-renewal and differentiation in human embryonic stem cells. Desbordes SC et al.

Abstract

High-throughput screening (HTS) of chemical libraries has become a critical tool in basic biology and drug discovery. However, its implementation and the adaptation of high-content assays to human embryonic stem cells (hESCs) have been hampered by multiple technical challenges. Here we present a strategy to adapt hESCs to HTS conditions, resulting in an assay suitable for the discovery of small molecules that drive hESC self-renewal or differentiation. Use of this new assay has led to the identification of several marketed drugs and natural compounds promoting short-term hESC maintenance and compounds directing early lineage choice during differentiation. Global gene expression analysis upon drug treatment defines known and novel pathways correlated to hESC self-renewal and differentiation. Our results demonstrate feasibility of hESC-based HTS and enhance the repertoire of chemical compounds for manipulating hESC fate. The availability of high-content assays should accelerate progress in basic and translational hESC biology.
Antimicrobial agents and chemotherapy 1998 OCT Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases. Takei M et al.

Abstract

We determined the inhibitory activities of gatifloxacin against Staphylococcus aureus topoisomerase IV, Escherichia coli DNA gyrase, and HeLa cell topoisomerase II and compared them with those of several quinolones. The inhibitory activities of quinolones against these type II topoisomerases significantly correlated with their antibacterial activities or cytotoxicities (correlation coefficient [r] = 0.926 for S. aureus, r = 0.972 for E. coli, and r = 0.648 for HeLa cells). Gatifloxacin possessed potent inhibitory activities against bacterial type II topoisomerases (50% inhibitory concentration [IC50] = 13.8 microg/ml for S. aureus topoisomerase IV; IC50 = 0.109 microg/ml for E. coli DNA gyrase) but the lowest activity against HeLa cell topoisomerase II (IC50 = 265 microg/ml) among the quinolones tested. There was also a significant correlation between the inhibitory activities of quinolones against S. aureus topoisomerase IV and those against E. coli DNA gyrase (r = 0.969). However, the inhibitory activity against HeLa cell topoisomerase II did not correlate with that against either bacterial enzyme. The IC50 of gatifloxacin for HeLa cell topoisomerase II was 19 and was more than 2,400 times higher than that for S. aureus topoisomerase IV and that for E. coli DNA gyrase. These ratios were higher than those for other quinolones, indicating that gatifloxacin possesses a higher selectivity for bacterial type II topoisomerases.
View All Publications

Contact STEMCELL Technologies

Our Customer Service, Sales, and Product and Scientific Support departments in North America are available between 6 am and 5 pm Pacific Time (9 am and 8 pm Eastern Time). One of our representatives will be happy to help you by telephone or email. Please complete the form to contact us by email. A representative will get back to you shortly.
  •  

StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.